acetylcholine

Acetylcholine

Introduction

Acetylcholine is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Acetylcholine (ACh) is a neurotransmitter essential for synaptic transmission in both the central and peripheral nervous systems. It mediates neuromuscular junction signaling, autonomic function, and cognitive processes including learning, memory, attention, and arousal. The cholinergic[@whitehouse1982] system is profoundly affected in [Alzheimer's Disease][mesulam1983], where degeneration of basal forebrain cholinergic[@whitehouse1982] [neurons](/entities/neurons) is a hallmark pathological feature. [@mesulam1983]
This relationship forms the basis of the cholinergic[@whitehouse1982] hypothesis -- the first major neurochemical theory of [@greig2005]
[Alzheimer's Disease](/diseases/alzheimers-disease)[@mesulam1983] -- and led to the development of [cholinesterase inhibitors](/entities/cholinesterase-inhibitors) as [@hasselmo2006]
the first approved symptomatic treatments ([Bartus et al., 1982](https://pubmed.ncbi.nlm.nih.gov/6289717/); [Francis et al., [@birks2006]
1999](https://pubmed.ncbi.nlm.nih.gov/9932142/)) ([Hampel et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29850777/)). [@wang2000]

Chemistry and Synthesis

Chemical Properties

...

Acetylcholine

Introduction

Acetylcholine is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Acetylcholine (ACh) is a neurotransmitter essential for synaptic transmission in both the central and peripheral nervous systems. It mediates neuromuscular junction signaling, autonomic function, and cognitive processes including learning, memory, attention, and arousal. The cholinergic[@whitehouse1982] system is profoundly affected in [Alzheimer's Disease][mesulam1983], where degeneration of basal forebrain cholinergic[@whitehouse1982] [neurons](/entities/neurons) is a hallmark pathological feature. [@mesulam1983]
This relationship forms the basis of the cholinergic[@whitehouse1982] hypothesis -- the first major neurochemical theory of [@greig2005]
[Alzheimer's Disease](/diseases/alzheimers-disease)[@mesulam1983] -- and led to the development of [cholinesterase inhibitors](/entities/cholinesterase-inhibitors) as [@hasselmo2006]
the first approved symptomatic treatments ([Bartus et al., 1982](https://pubmed.ncbi.nlm.nih.gov/6289717/); [Francis et al., [@birks2006]
1999](https://pubmed.ncbi.nlm.nih.gov/9932142/)) ([Hampel et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29850777/)). [@wang2000]

Chemistry and Synthesis

Chemical Properties

Acetylcholine is a quaternary ammonium ester: [@scarpa2020]

• Chemical formula: C7H16NO2+
• Molecular weight: 146.21 Da
• Synthesis enzyme: Choline acetyltransferase (ChAT)
• Degradation enzyme: Acetylcholinesterase (AChE); half-life in the synapse is approximately 1-2 milliseconds

Biosynthesis and Metabolism

ACh is synthesized in cholinergic[@whitehouse1982] [neurons](/entities/neurons) through a single enzymatic step: [@hampel2018]

Choline uptake: The high-affinity choline transporter (CHT1/SLC5A7) imports choline from the extracellular space -- the rate-limiting step in ACh synthesis

Acetylation: ChAT catalyzes the transfer of an acetyl group from acetyl-CoA to choline, producing acetylcholine[@greig2005]

and senile dementia: loss of [neurons](/entities/neurons) in the basal forebrain. Science. 1982;215(4537]:1237-1239. [@ferreiravieira2016]
[doi:10.1126/science.7058341](https://pubmed.ncbi.nlm.nih.gov/7058325/)" data-ref-title="Price DL, Struble RG, et al. Alzheimer's Disease[@greig2005]
and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215(4537]:1237-1239.
[doi:10.1126/science.7058341](https://pubmed.ncbi.nlm.nih.gov/7058325/)" data-ref-authors="[Whitehouse PJ" data-ref-journal="Price DL,
Struble RG, et al. Alzheimer's Disease[@greig2005] and senile dementia: loss of neurons in the basal forebrain. Science" data-ref-year="1982"
data-ref-url="https://pubmed.ncbi.nlm.nih.gov/7058325/" title="[Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's Disease[@greig2005] and
senile dementia: loss of neurons in the basal forebrain. Science. 1982;215(4537]:1237-1239.
[doi:10.1126/science.7058341](https://pubmed.ncbi.nlm.nih.gov/7058325/)">[@whitehouse1982]

Vesicular packaging: The vesicular acetylcholine[@whitehouse1982] transporter (VAChT) loads ACh into synaptic vesicles

Release: Calcium-dependent exocytosis releases ACh into the synaptic cleft

Degradation: AChE rapidly hydrolyzes ACh to choline and acetate; choline is recycled via CHT1

Butyrylcholinesterase (BuChE), expressed in glia and plasma, provides a secondary degradation pathway that becomes more important as disease progresses and AChE levels decline ([Greig et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15853536/)) ([Francis et al., 1999](https://pubmed.ncbi.nlm.nih.gov/9932142/)).

Cholinergic Circuits in the Brain

Basal Forebrain Cholinergic System (BFCS)

The BFCS provides the primary cholinergic[@whitehouse1982] innervation to the cerebral [cortex](/brain-regions/cortex) and [hippocampus](/brain-regions/hippocampus)
and is critical for cognitive function: ([Mesulam et al., 1983](https://pubmed.ncbi.nlm.nih.gov/6616267/))

• [Nucleus basalis of Meynert (NBM)](/brain-regions/nucleus-basalis-of-meynert): The largest cholinergic[@whitehouse1982] cell group; projects widely to the neocortex, particularly prefrontal, parietal, and temporal [cortex](/brain-regions/cortex). Essential for attention, arousal, and cortical plasticity ([Mesulam et al., 1983](https://pubmed.ncbi.nlm.nih.gov/6616267/)) ([Ballinger et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27657448/))
• Medial septal nucleus/Diagonal band of Broca: Projects to the [hippocampus](/brain-regions/hippocampus) and entorhinal [cortex](/brain-regions/cortex); critical for spatial memory, theta rhythm generation, and memory consolidation
• Substantia innominata: Provides cholinergic[@whitehouse1982] input to the amygdala and olfactory [cortex](/brain-regions/cortex)

Brainstem Cholinergic System

• Pedunculopontine nucleus (PPN): Modulates arousal, REM sleep, locomotion; projects to thalamus and basal ganglia
• Laterodorsal tegmental nucleus (LDT): Involved in reward, attention, and arousal
• Cranial nerve motor nuclei: Innervate muscles of the head and neck

Striatal Cholinergic Interneurons

Large aspiny cholinergic[@whitehouse1982] interneurons in the striatum modulate dopaminergic
signaling and are relevant to [Parkinson's disease](/diseases/parkinsons-disease) and [Huntington's disease](/mechanisms/huntington-pathway) ([Whitehouse et al.,
1982](https://pubmed.ncbi.nlm.nih.gov/7058325/)).

Receptor Types

ACh acts through two major receptor superfamilies with distinct pharmacology and signaling:

Muscarinic Receptors (mAChRs) -- G Protein-Coupled Receptors

| Subtype | G Protein | CNS Distribution | Key Functions |
|---------|-----------|-----------------|---------------|
| M1 | Gq/11 | [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus) | Memory, attention, cortical plasticity |
| M2 | Gi/o | Brainstem, thalamus, presynaptic terminals | Autoreceptor; inhibits ACh release |
| M3 | Gq/11 | Hypothalamus, salivary glands | Smooth muscle, glandular secretion |
| M4 | Gi/o | Striatum, [cortex](/brain-regions/cortex) | Modulates dopamine release; motor control |
| M5 | Gq/11 | Substantia nigra, VTA | Modulates dopamine neuron activity |

M1 receptors are the primary postsynaptic target in the [cortex](/brain-regions/cortex) and [hippocampus](/brain-regions/hippocampus) and are key mediators of cholinergic[@greig2005]
and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215(4537]:1237-1239.
[doi:10.1126/science.7058341](https://pubmed.ncbi.nlm.nih.gov/7058325/)" data-ref-title="Price DL, Struble RG, et al. Alzheimer's Disease[@greig2005]
and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215(4537]:1237-1239.
[doi:10.1126/science.7058341](https://pubmed.ncbi.nlm.nih.gov/7058325/)" data-ref-authors="[Whitehouse PJ" data-ref-journal="Price DL,
Struble RG, et al. Alzheimer's Disease[@greig2005] and senile dementia: loss of neurons in the basal forebrain. Science" data-ref-year="1982"
data-ref-url="https://pubmed.ncbi.nlm.nih.gov/7058325/" title="[Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's Disease[@greig2005] and
senile dementia: loss of neurons in the basal forebrain. Science. 1982;215(4537]:1237-1239.
[doi:10.1126/science.7058341](https://pubmed.ncbi.nlm.nih.gov/7058325/)">[@whitehouse1982] cognitive enhancement. M1 positive allosteric
modulators (PAMs) are under investigation as potential AD therapeutics ([Scarpa et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32291268/)).

Nicotinic Receptors (nAChRs) -- Ligand-Gated Ion Channels

| Subtype | Composition | CNS Distribution | Key Functions |
|---------|------------|-----------------|---------------|
| alpha4-beta2 | (alpha4)2(beta2)3 or (alpha4)3(beta2)2 | Widespread; thalamus, cortex | High-affinity nicotine binding; attention |
| alpha7 | (alpha7)5 | [hippocampus](/brain-regions/hippocampus), cortex, [microglia](/cell-types/microglia).

Cholinergic Dysfunction in Alzheimer's Disease

The Cholinergic Hypothesis

First articulated by Bartus et al. (1982) and subsequently refined, the cholinergic[@whitehouse1982] hypothesis proposes that degeneration of basal
forebrain cholinergic[@whitehouse1982] [neurons](/entities/neurons) and the resulting cortical/hippocampal
cholinergic[@whitehouse1982] deficit is a primary contributor to cognitive decline
in AD ([Bartus et al., 1982](https://pubmed.ncbi.nlm.nih.gov/6289717/)). For a detailed discussion, see Cholinergic Hypothesis in
Alzheimer's Disease.

Pathological Changes

AD is characterized by severe and progressive cholinergic[@whitehouse1982] deficits:

• Neuronal loss: 30-75% loss of cholinergic[@whitehouse1982] [neurons](/entities/neurons) in the [nucleus basalis of Meynert](/brain-regions/nucleus-basalis-of-meynert), with the most severe losses in advanced disease ([Whitehouse et al., 1982](https://pubmed.ncbi.nlm.nih.gov/7058325/))
• Reduced ChAT activity: 50-90% decrease in cortical ChAT activity, correlating with dementia severity
• Decreased ACh release: Impaired synthesis and release of acetylcholine[@whitehouse1982]
• Receptor changes: alpha7 and alpha4-beta2 nAChR downregulation; relatively preserved M1 mAChR expression (though with uncoupling from G proteins)
• Axonal degeneration: Loss of cholinergic[@whitehouse1982] projections from NBM to cortex precedes neuronal cell body loss
• Selective vulnerability: NBM cholinergic[@whitehouse1982] [neurons](/entities/neurons) are particularly susceptible to tau] pathology], [amyloid-beta](/proteins/amyloid-beta) toxicity, and neuroinflammation

Interactions with Other Pathologies

Cholinergic dysfunction intersects with multiple AD pathological processes:

• [amyloid-beta](/proteins/amyloid-beta): Directly impairs cholinergic[@whitehouse1982] neurotransmission; [amyloid-beta](/proteins/amyloid-beta) oligomers inhibit ACh release and ChAT activity
• [Tau](/proteins/tau) pathology]: NFTs accumulate early in basal forebrain cholinergic[@whitehouse1982] neurons; tau] hyperphosphorylation] impairs axonal transport
• neuroinflammation: Activated [microglia release factors toxic to cholinergic[@whitehouse1982] neurons; the cholinergic[@whitehouse1982] anti-inflammatory pathway is compromised
• Neurotrophic factor withdrawal: Loss of NGF retrograde signaling contributes to cholinergic[@whitehouse1982] atrophy

Cholinergic Involvement in Other Neurodegenerative Diseases

Parkinson's Disease

• Cholinergic deficits in the basal forebrain and brainstem (PPN) contribute to cognitive impairment and gait/balance dysfunction
• PDD and DLB show cholinergic[@whitehouse1982] deficits comparable to or exceeding those in AD
• [Rivastigmine](/therapeutics/rivastigmine) is approved for PD dementia

Lewy Body Dementia

• Severe cholinergic[@whitehouse1982] deficits; often responds well to [cholinesterase inhibitors](/entities/cholinesterase-inhibitors)
• NBM degeneration with Lewy body pathology

Huntington's Disease

• Striatal cholinergic[@whitehouse1982] interneurons are relatively preserved but dysfunctional
• Altered ACh-dopamine balance contributes to motor and cognitive symptoms

Clinical Applications

Cholinesterase Inhibitors

[Cholinesterase inhibitors](/entities/cholinesterase-inhibitors) remain the primary symptomatic treatment for AD:

| Drug | Target | Formulation | Indication |
|------|--------|------------|------------|
| [Donepezil](/therapeutics/donepezil) (Aricept) | Selective AChE | Oral (QD) | Mild-severe AD |
| [Rivastigmine](/therapeutics/rivastigmine) (Exelon) | AChE + BuChE | Oral, transdermal | Mild-moderate AD, PDD |
| Galantamine (Razadyne) | AChE + alpha7 nAChR PAM | Oral (ER) | Mild-moderate AD |

These provide modest but clinically meaningful symptomatic benefits in cognition, function, and behavior. They do not modify disease progression ([Birks, 2006](https://pubmed.ncbi.nlm.nih.gov/16437532/)).

Emerging Cholinergic Therapies

• M1 mAChR PAMs/agonists: Selective M1 activation to enhance cognition without peripheral side effects
• alpha7 nAChR agonists: Anti-inflammatory and procognitive; under clinical investigation
• Gene therapy: AAV-mediated NGF delivery to basal forebrain to support cholinergic[@whitehouse1982] neuron survival
• Deep brain stimulation: NBM-DBS under investigation for cognitive enhancement in AD
• Combination therapies: Cholinesterase inhibitors combined with [anti-amyloid immunotherapy](/therapeutics/immunotherapy) (e.g., [lecanemab](/therapeutics/lecanemab), [donanemab)

External Links

• [PubChem: Acetylcholine)](https://pubchem.ncbi.nlm.nih.gov/compound/187)
• [IUPHAR: Acetylcholine Receptors](https://www.guidetopharmacology.org/GRAC/NaturaLigandDisplayForward?ligandId=294)
• [Allen Human Brain Atlas: CHAT](https://human.brain-map.org/microarray/search/show?search_term=CHAT)

See Also

• [Microglia](/entities/microglia)

Brain Atlas Resources

• Allen Human Brain Atlas: [Acetylcholine expression search](https://human.brain-map.org/microarray/search/show?search_term=Acetylcholine)
• Allen Mouse Brain Atlas: [Acetylcholine search](https://mouse.brain-map.org/search/index.html?query=Acetylcholine)
• Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
• BrainSpan Developmental Transcriptome: [Acetylcholine developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=Acetylcholine)

Background

The study of Acetylcholine has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

PMID: 7058325(https://pubmed.ncbi.nlm.nih.gov/7058325/)

[Mesulam MM, Mufson EJ, Levey AI, et al., Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis, and substantia innominata. J Comp Neurol. 1983;214(2):170-197. [doi:10.1002/cne.902140206 (1983)](https://pubmed.ncbi.nlm.nih.gov/6616267/)

PMID: 15853536(https://pubmed.ncbi.nlm.nih.gov/15853536/) PMID: 17011181(https://pubmed.ncbi.nlm.nih.gov/17011181/) PMID: 16437532(https://pubmed.ncbi.nlm.nih.gov/16437532/)

[Wang HY, Lee DH, D'Andrea MR, et al, beta-Amyloid(1-42] binds to alpha7 nicotinic acetylcholine[1] receptor with high affinity (2000)]([PMID:10681545)(https://pubmed.ncbi.nlm.nih.gov/10681545/))

[Unknown, Scarpa M, Bhattacharyya S, Bhatt S. Muscarinic M1 receptor positive allosteric modulators: bridging the gap between theoretical models and clinical applications. ACS Chem Neurosci. 2020;11(9):1269-1283. [doi:10.1021/acschemneuro.0c00088 (2020)](https://pubmed.ncbi.nlm.nih.gov/32291268/)

PMID: 29850777(https://pubmed.ncbi.nlm.nih.gov/29850777/) PMID: 26813123(https://pubmed.ncbi.nlm.nih.gov/26813123/)

Pathway Diagram

The following diagram shows the key molecular relationships involving acetylcholine discovered through SciDEX knowledge graph analysis:

Pathway Diagram

The following diagram shows the key molecular relationships involving acetylcholine discovered through SciDEX knowledge graph analysis: